New Imaging Biomarkers Predictive of MA Progression

Launched by POITIERS UNIVERSITY HOSPITAL · Jun 30, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating new ways to understand how Alzheimer's disease (AD) progresses by using advanced imaging techniques. Researchers want to see if a special type of MRI, called 7T MRI, can provide better insights into changes in brain metabolism that occur with AD. This study will involve patients with early-stage Alzheimer's who will undergo both MRI and Magnetic Resonance Spectroscopy (MRS) to look at brain function without any additional risks.

To participate in this trial, individuals need to be French-speaking, between 60 and 90 years old, and have a confirmed diagnosis of Alzheimer's disease. They should also have experienced a decline in cognitive abilities for at least six months. Participants will have the opportunity to contribute to important research that could improve our understanding of Alzheimer's and potentially lead to better treatment options. If you or someone you know fits these criteria and is interested in learning more, please reach out for additional information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • French-speaking patients aged 60 to 90 years,
• • Patient in the context of Alzheimer's disease \* for which imaging after MRI is prescribed as part of the usual diagnostic process,
• • \*Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR/RI defined by a sum of LR \< 17/48 and sum of RT \< 40/48 +/- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +/- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery).
• • MMSE score ≥18,
• • Written informed consent after the patient has been informed,
• • Progressive decline for at least 6 months.
• Exclusion Criteria:
• • --Partially or completely illiterate patient unable to read and write,
• • Patient with an absolute contraindication to 7T MRI
• • Severe psychiatric pathology not balanced,
• • Non-degenerative neurological disease (stroke, multiple sclerosis ...),
• • Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score \> 3)